Dr Kola Tytler MBBS CertHE MBA MRCGPClinical Lead • iatroX
The current first-line treatments for managing active Crohn's disease in adults include:
- Offer monotherapy with a conventional glucocorticosteroid (such as prednisolone, methylprednisolone, or intravenous hydrocortisone) to induce remission in people with a first presentation or a single inflammatory exacerbation of Crohn's disease in a 12‑month period NICE CKS.
- Consider adding methotrexate to a conventional glucocorticosteroid or budesonide to induce remission if the person cannot tolerate azathioprine or mercaptopurine, or if TPMT activity is deficient NICE CKS.
- In cases of severe active Crohn's disease, infliximab or adalimumab may be used if conventional therapy has not responded or is not tolerated, given as a planned course until treatment failure or 12 months, with reassessment for ongoing treatment NICE CKS.